review · Molecular Biology Reports
Producing nanoparticles through biological systems offers an inexpensive and environmentally safe method for creating targeted drug delivery platforms. This approach is particularly relevant for enhancing anticancer treatments such as sorafenib, a multi-kinase inhibitor commonly used against liver cancer. Although sorafenib inhibits molecularly targeted kinases, its effectiveness is often hindered by low bioavailability, caused by poor water solubility and rapid bodily elimination, as well as the emergence of drug resistance. Advanced nanoformulations can enhance both the targeting ability and bioavailability of the drug. In particular, materials with magnetic properties can serve as carriers that guide the medicine precisely to tumour sites. This precise delivery allows for a reduced therapeutic dosage while avoiding harm to healthy cells.
Conventional liver cancer medications often struggle with poor absorption and unintended damage to healthy tissue. Using environmentally friendly biological methods to engineer nano-sized delivery vehicles can improve the performance of existing drugs like sorafenib. By directing medication straight to tumours, this targeted approach has the potential to make cancer therapies both more effective and less toxic for patients.
This work points towards applications in targeted oncology drug delivery, which could benefit pharmaceutical developers and nanomedicine innovators seeking greener, lower-cost production methods. As the abstract presents a broad review of mechanisms and nanoformulation concepts rather than validated product testing, the underlying technologies remain at an early research stage.
AI-generated from the published abstract. Always read the original work before citing.
This review presents an overview of one of the effective strategies for improving the anticancer impact of many drugs including sorafenib using a drug delivery system by employing nanoparticles that is produced through a biological system. The biological process has a lot of benefits, including being inexpensive and safe for the environment. Sorafenib is one of a multi-kinase inhibitor that inhibits molecularly targeted kinases. Because of its poor pharmacokinetic characteristics, such as fast elimination and limited water solubility, the bioavailability of Sorafenib is extremely low. More intelligent nano formulations of sorafenib have been developed to boost both the drug's target ability and bioavailability. Researchers in a wide variety of sectors, including nanomedicine, have recently been interested in the topic of nanotechnology. It is possible for the body to develop resistance to widely used drugs available for treatment of liver cancer, including sorafenib. As a result, our goal of this research is to highlight the efficacy of nanomedicine-based drug delivery system to enhance drug's cancer-fighting properties. Because of their magnetic properties, certain nanoparticle materials can be employed as a carrier for the medicine to the exact place where the cancer is located. This can lower the amount of the drug that is administered with no impact on the normal cells.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s11033-023-08823-5
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
